- Home
- BZFD vs SGMT Comparison
BZFD vs SGMT Comparison
Compare BZFD & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BZFD
- SGMT
- Stock Information
- Founded
- BZFD 2006
- SGMT 2006
- Country
- BZFD United States
- SGMT United States
- Employees
- BZFD N/A
- SGMT N/A
- Industry
- BZFD Movies/Entertainment
- SGMT
- Sector
- BZFD Consumer Discretionary
- SGMT
- Exchange
- BZFD Nasdaq
- SGMT Nasdaq
- Market Cap
- BZFD 113.4M
- SGMT 93.7M
- IPO Year
- BZFD N/A
- SGMT 2023
- Fundamental
- Price
- BZFD $3.06
- SGMT $4.73
- Analyst Decision
- BZFD
- SGMT Strong Buy
- Analyst Count
- BZFD 0
- SGMT 5
- Target Price
- BZFD N/A
- SGMT $21.60
- AVG Volume (30 Days)
- BZFD 889.0K
- SGMT 792.4K
- Earning Date
- BZFD 11-12-2024
- SGMT 11-13-2024
- Dividend Yield
- BZFD N/A
- SGMT N/A
- EPS Growth
- BZFD N/A
- SGMT N/A
- EPS
- BZFD N/A
- SGMT N/A
- Revenue
- BZFD $231,670,000.00
- SGMT N/A
- Revenue This Year
- BZFD $35.96
- SGMT N/A
- Revenue Next Year
- BZFD $4.81
- SGMT N/A
- P/E Ratio
- BZFD N/A
- SGMT N/A
- Revenue Growth
- BZFD 6.51
- SGMT N/A
- 52 Week Low
- BZFD $0.64
- SGMT $2.31
- 52 Week High
- BZFD $4.56
- SGMT $20.71
- Technical
- Relative Strength Index (RSI)
- BZFD 58.91
- SGMT 41.81
- Support Level
- BZFD $2.71
- SGMT $5.61
- Resistance Level
- BZFD $3.56
- SGMT $6.40
- Average True Range (ATR)
- BZFD 0.29
- SGMT 0.53
- MACD
- BZFD 0.06
- SGMT -0.16
- Stochastic Oscillator
- BZFD 58.33
- SGMT 8.24
About BZFD BuzzFeed Inc.
BuzzFeed Inc is a tech-powered, diversified media company that reaches hundreds of millions globally through its cross-platform news and entertainment network. The company produces articles, lists, quizzes, videos, and original series; lifestyle content through brands including Tasty, social food network; original reporting and investigative journalism through BuzzFeed News and HuffPost; an industry- affiliate business, strategic partnerships, licensing and product development through BuzzFeed Commerce; and original productions across broadcast, cable, SVOD, film and digital platforms for BuzzFeed Studios.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).